Articles from Context Therapeutics Inc.

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers

Mr. Pasternak brings decades of global pharmaceutical leadership experience

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November:

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

Context to obtain exclusive development and commercialization rights to BA3362

The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers

Financing includes new and existing leading healthcare investors

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

CTIM-76 IND filing on track for late March 2024

CTIM-76 IND filing on track for late Q1 2024

CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.

Company expects its cash and cash equivalents will continue to fund operations into late 2024

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023. Details of the events are as follows:

CTIM-76 IND filing on track for Q1 2024

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023. Details of the events are as follows:

Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program

Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET

ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage

First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer

Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate

Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer

CTIM-76 named as lead candidate to target Claudin 6 positive cancers

Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials